Previous Close | 4.6600 |
Open | 4.7500 |
Bid | 4.8400 x 300 |
Ask | 4.9100 x 200 |
Day's Range | 4.6900 - 5.0600 |
52 Week Range | 1.5700 - 8.4000 |
Volume | |
Avg. Volume | 1,742,774 |
Market Cap | 444.77M |
Beta (5Y Monthly) | 1.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.